[HTML][HTML] Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
Journal of Clinical Oncology, 2016•ncbi.nlm.nih.gov
Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term
efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic
phase (CP) treated with dasatinib or imatinib.
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term
efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic
phase (CP) treated with dasatinib or imatinib.
Abstract
Purpose
We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib or imatinib.
ncbi.nlm.nih.gov